Guidance Document for Industry - Review of Drug Brand Names

To provide market authorization holders direction on the process to be followed and information to be submitted to Health Canada regarding the potential for a proposed name to be misleading or confused with another product authorized for use in Canada with the aim of preventing medication errors.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Ligne directrice à intention de l'industrie - Examen des marques nominatives de médicament
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2014-10-22 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Document d'orientation pour l'industrie", "examen des noms de marque de médicaments", "autorisation de mise en marché", "nom proposé trompeur", "confondu avec un autre produit", "autorisé pour utilisation", "prévention des erreurs de médication"], "en": ["Guidance document for industry", "review of drug brand names", "market authorization", "a proposed name to be misleading", "confused with another product", "authorized for use", "preventing medication errors"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source